|
|
(68 intermediate revisions by the same user not shown) |
Line 1: |
Line 1: |
| {| class="prettytable" style="font-size: 12px; font-family: Arial;" | | {| class="prettytable" style="font-size: 12px; font-family: Arial;" |
| |- | | |- |
| ! Antibiotic | | ! Antibiotic Agent |
| ! Antimicrobial Spectrum | | ! Antimicrobial Spectrum |
| ! Dosing Information | | ! Dosing Information |
| ! Adverse Reaction | | ! Notable Adverse Reaction |
| |- | | |- |
| | '''Amikacin''' | | | '''Amikacin''' |
Line 37: |
Line 37: |
| * Rash | | * Rash |
| * Diarrhea | | * Diarrhea |
| * Abdominal cramping | | * Cramping |
| |- | | |- |
| | '''Amoxicillin-Clavulanate''' | | | '''Amoxicillin-Clavulanate''' |
Line 65: |
Line 65: |
| | | | | |
| * Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | | * Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (≤ 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) |
| * Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/ kg/24 hr divided q 8 hr IV or IM (1,200 - 2,000 g); 100 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g) | | * Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV or IM q 12 hr (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 100 mg/kg/24 hr divided q 6 hr IV or IM (> 2,000 g) |
| * Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM | | * Children: 100-200 mg/kg/24 hr divided q 6 hr IV or IM |
| * Adults: 250-500 mg q 4-8 hr IV or IM | | * Adults: 250-500 mg q 4-8 hr IV or IM |
Line 71: |
Line 71: |
| * Diarrhea | | * Diarrhea |
| |- | | |- |
| | '''Ampicillin-sulbactam''' | | | '''Ampicillin-Sulbactam''' |
| | | | | |
| * S. aureus | | * S. aureus |
Line 107: |
Line 107: |
| | | | | |
| * Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) | | * Neonates (postnatal age ≤ 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) |
| * Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1,200 - 2,000 g); 120 mg/kg/24 hr divided q 6-8 hr IV or IM (> 2,000 g) | | * Neonates (postnatal age > 7 days): 60 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 90 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 120 mg/kg/24 hr divided q 6-8 hr IV or IM (> 2,000 g) |
| * Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM | | * Children: 90-120 mg/kg/24 hr divided q 6-8 hr IV or IM |
| * Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr) | | * Adults: 1-2 g IV or IM q 8-12 hr (max dose: 8 g/24 hr) |
Line 142: |
Line 142: |
| * Rash | | * Rash |
| * Eosinophilia | | * Eosinophilia |
| * Serum sickness | | * Serum sickness-like reaction |
| |- | | |- |
| | | '''Cefadroxil''' |
| | | | | |
| '''Cefadroxil'''
| | * S. aureus |
| | | * Streptococcus |
| Duricef, Ultracef.
| | * E. coli |
| | | * Klebsiella |
| | * Proteus |
| | | | | |
| '''1st-generation cephalosporin active against ''S. aureus, Streptococcus, E. coli, Klebsiella, ''and ''Proteus.'''''
| | * Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g) |
| | | * Adults: 250-500 mg q 8-12 hr PO |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Long half-life permits q 12-24 hr dosing.
| | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Cefazolin''' |
| | | |
| | * S. aureus |
| | * Streptococcus |
| | * E. coli |
| | * Klebsiella |
| | * Proteus |
| | | | | |
| Capsule: 500 mg.
| | * Neonates (postnatal age ≤ 7 days): 40 mg/kg/24 hr divided q 12 hr IV or IM |
| | | * Neonates (postnatal age > 7 days): 40-60 mg/kg/24 hr divided q 8 hr IV or IM |
| | * Children: 50-100 mg/kg/24 hr divided q 8 hr IV or IM |
| | * Adults: 0.5-2g q 8 hr IV or IM (max dose: 12 g/24 hr) |
| | | | | |
| Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g).
| | * Rash |
| | | * Eosinophilia |
| |
| |
| Drug interaction: Probenecid.
| |
| | |
| |- | | |- |
| | | '''Cefdinir''' |
| | | | | |
| Tablet: 1,000 mg.
| | * Extended-spectrum cephalosporin |
| | |
| | | | | |
| | | * Children: 14 mg/kg/24 hr in 1 or 2 doses PO (max dose: 600 mg/24 hr) |
| | | * Adults: 600 mg q 24 hr PO |
| | | | | |
| | | * Diarrhea |
| | |
| |- | | |- |
| | | '''Cefepime''' |
| | | | | |
| Suspension: 125 mg/5 mL, 250 mg/5 mL, 500 mg/5 mL.
| | * Gram-positive bacteria |
| | | * Gram-negative bacteria including P. aeruginosa |
| | | | | |
| Adults: 250-500 mg q 8-12 hr PO.
| | * Children: 100-150 mg/kg/24 hr q 8-12 hr IV or IM |
| | | * Adults: 2-4 g/24 hr q 12 hr IV or IM |
| | | | | |
| | | * Diarrhea |
| | | * Nausea |
| | * Vaginal candidiasis |
| | * Rash |
| | * Eosinophilia |
| |- | | |- |
| | | '''Cefixime''' |
| | | | | |
| '''Cefazolin'''
| | * Streptococci |
| | | * H. influenzae |
| Ancef, Kefzol.
| | * M. catarrhalis |
| | | * Neisseria gonorrhoeae |
| | * Serratia marcescens |
| | * P. vulgaris |
| | | | | |
| '''1st generation cephalosporin active against ''S. aureus, Streptococcus, E. coli, Klebsiella, ''and ''Proteus.'''''
| | * Children: 8 mg/kg/24 hr divided q 12-24 hr PO |
| | | * Adults: 400 mg/24 hr divided q 12-24 hr PO |
| | | | | |
| ''Caution: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Does not adequately penetrate CNS.
| | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Cefoperazone''' |
| | | | | |
| Injection.
| | * Gram-positive pathogens |
| | | * Gram-negative pathogens |
| | | | | |
| Neonates: Postnatal age ≤7 days 40 mg/kg/24 hr divided q 12 hr IV or IM; 7 days 40-60 mg/kg/24 hr divided q 8 hr IV or IM. | | * Neonates: 100 mg/kg/24 hr divided q 12 hr IV or IM |
| | | * Children: 100-150 mg/kg/24 hr divided q 8-12 hr IV or IM |
| | * Adults: 2-4 g/24 hr divided q 8-12 hr IV or IM (max dose: 12 g/24 hr) |
| | | | | |
| Drug interaction: Probenecid.
| | * Hypoprothrombinemia |
| | | * Disulfiram-life reaction |
| |- | | |- |
| | | '''Cefotaxime''' |
| | | | | |
| | | * Gram-positive pathogens |
| | | * Gram-negative pathogens |
| | | | | |
| Children: 50-100 mg/kg/24 hr divided q 8 hr IV or IM. | | * Neonates (postnatal age ≤ 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM |
| | | * Neonates (postnatal age > 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 150 mg/kg/24 hr divided q 8 hr IV or IM (> 1,200 g) |
| | * Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM |
| | * Adults: 1-2 g q 8-12 hr IV or IM (max dose: 12 g/24 hr) |
| | | | | |
| | | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Cefotetan''' |
| | | | | |
| | | * S. aureus |
| | | * Streptococcus |
| | * H. influenzae |
| | * E. coli |
| | * Klebsiella |
| | * Proteus |
| | * Bacteroides |
| | | | | |
| Adults: 0.5-2g q 8 hr IV or IM (max dose: 12 g/24 hr). | | * Children: 40-80 mg/kg/24 hr divided IV or IM q 12 hr |
| | | * Adults: 2-4 g/24 hr divided q 12 hr IV or IM (max dose: 6 g/24 hr) |
| | | | | |
| | | * Rash |
| | | * Eosinophilia |
| | * Hypoprothrombinemia |
| | * Disulfiram-life reaction |
| |- | | |- |
| | | '''Cefoxitin''' |
| | | | | |
| '''Cefdinir '''Omnicef. Capsule: 300 mg.
| | * S. aureus |
| | | * Streptococcus |
| Oral suspension: 125 mg/5 mL.
| | * H. influenzae |
| | | * E. coli |
| | * Klebsiella |
| | * Proteus |
| | * Bacteroides |
| | | | | |
| '''Extended-spectrum, semi-synthetic cephalosporin.'''
| | * Neonates: 70-100 mg/kg/24 hr divided q 8-12 hr IV or IM |
| | | * Children: 80-160 mg/kg/24 hr divided q 6-8 hr IV or IM |
| Children 6 mo-12 yr: 14 mg/kg/24 hr in 1 or 2 doses PO (max dose: 600 mg/24 hr). | | * Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr) |
| | |
| Adults: 600 mg q 24 hr PO.
| |
| | |
| | | | | |
| ''Cautions: ''Reduce dosage in renal insufficiency (creatinine clearance 60 mL/min). Avoid taking concurrently with iron-containing products and antacids because absorption is markedly decreased; take at least 2 hr apart.
| | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Cefpodoxime''' |
| | | | | |
| | | * S. aureus |
| | | * Streptococcus |
| | * H. influenzae |
| | * M. catarrhalis |
| | * N. gonorrhoeae |
| | * E. coli |
| | * Klebsiella |
| | * Proteus |
| | | | | |
| | | * Children: 10 mg/kg/24 hr divided q 12 hr PO |
| | | * Adults: 200-800 mg/24 hr divided q 12 hr PO (max dose: 800 mg/24 hr) |
| | | | | |
| ''Drug interaction: ''Probenecid.
| | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Cefprozil''' |
| | | | | |
| '''Cefepime '''Maxipime. Injection.
| | * S. aureus |
| | | * Streptococcus |
| | * H. influenzae |
| | * E. coli |
| | * M. catarrhalis |
| | * Klebsiella |
| | * Proteus |
| | | | | |
| '''Expanded-spectrum, 4th generation cephalosporin active against many gram-positive and gram-negative pathogens, including ''Pseudomonas aeruginosa ''many multidrug-resistant pathogens.'''
| | * Children: 30 mg/kg/24 hr divided q 8-12 hr PO |
| | | * Adults: 500-1,000 mg/24 hr divided q 12 hr PO (max dose: 1.5 g/24 hr) |
| | | | | |
| ''Adverse events: ''Diarrhea, nausea, vaginal candidiasis
| | * Rash |
| | | * Eosinophilia |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated.
| |
| | |
| |- | | |- |
| | | '''Ceftazidime''' |
| | | | | |
| | | * Gram-positive pathogens |
| | | * Gram-negative pathogens including P. aeruginosa |
| | | | | |
| Children: 100-150 mg/kg/24 hr q 8-12 hr IV or IM. | | * Neonates (postnatal age ≤ 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM |
| | | * Neonates (postnatal age > 7 days): 100 mg/kg/24 hr divided q 12 hr IV or IM (< 1,200 g); 150 mg/kg/24 hr divided q 8 hr IV or IM (> 1,200 g) |
| | * Children: 150 mg/kg/24 hr divided q 8 hr IV or IM |
| | * Adults: 1-2 g q 8-12 hr IV or IM (max dose: 8-12 g/24 hr) |
| | | | | |
| ''Drug interaction: ''Probenecid.
| | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Ceftiaoxime''' |
| | | | | |
| | | * Gram-positive pathogens |
| | | * Gram-negative pathogens |
| | | | | |
| Adults: 2-4 g/24 hr q 12 hr IV or IM.
| | * Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM |
| | | * Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr) |
| | | | | |
| | | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Ceftriaxone''' |
| | | | | |
| '''Cefixime'''
| | * Gram-positive pathogens |
| | | * Gram-negative pathogens |
| Suprax.
| |
| | |
| Tablet: 200, 400 mg.
| |
| | |
| | | | | |
| '''3rd generation cephalosporin active against ''Streptococci, H. influenzae, M. catarrhalis, Neisseria gonorrhoeae, Serratia marcescens, ''and ''P. vulgaris. ''No antistaphylococcal or antipseudomonal activity.'''
| | * Neonates: 50-75 mg/kg q 24 hr IV or IM |
| | | * Children: 50-75 mg/kg q 24 hr IV or IM |
| | * Adults: 1-2 g q 24 hr IV or IM (max dose: 4 g/24 hr) |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Does not adequately penetrate CNS.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |- | | |- |
| | | '''Cefuroxime''' |
| | | | | |
| Suspension: 100 mg/5 mL.
| | * S. aureus |
| | | * Streptococcus |
| | * H. influenzae |
| | * E. coli |
| | * M. catarrhalis |
| | * Klebsiella |
| | * Proteus |
| | | |
| | * Neonates: 40-100 mg/kg/24 hr divided q 12 hr IV or IM |
| | * Children: 200-240 mg/kg/24 hr divided q 8 hr IV or IM; 20-30 mg/kg/24 hr divided q 8 hr PO |
| | * Adults: 750-1,500 mg q 8 hr IV or IM (max dose: 6 g/24 hr) |
| | | | | |
| Children: 8 mg/kg/24 hr divided q 12-24 hr PO.
| | * Rash |
| | | * Eosinophilia |
| |
| |
| | |
| | |
| |- | | |- |
| | | '''Cephalexin''' |
| | | | | |
| | | * S. aureus |
| | | * Streptococcus |
| | * E. coli |
| | * Klebsiella |
| | * Proteus |
| | | |
| | * Children: 25-100 mg/kg/24 hr divided q 6-8 hr PO |
| | * Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr) |
| | | | | |
| Adults: 400 mg/24 hr divided q 12-24 hr PO.
| | * Rash |
| | | * Eosinophilia |
| |
| |
| | |
| | |
| |- | | |- |
| | | '''Cephradine''' |
| | | | | |
| '''Cefoperazone sodium'''
| | * S. aureus |
| | | * Streptococcus |
| Cefobid. Injection.
| | * E. coli |
| | | * Klebsiella |
| | * Proteus |
| | | | | |
| '''3rd generation cephalosporin active against many gram-positive and gram-negative pathogens.'''
| | * Children: 50-100 mg/kg/24 hr divided q 6-12 hr PO |
| | | * Adults: 250-500 mg q 6-12 hr PO (max dose: 4 g/24 hr) |
| Neonates: 100 mg/kg/24 hr divided q 12 hr IV or IM. Children: 100-150 mg/kg/24 hr divided q 8-12 hr IV or IM.
| |
| | |
| Adults: 2-4 g/24 hr divided q 8-12 hr IV or IM (max dose: 12 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''Highly protein bound cephalosporin with limited potency reflected by weak antipseudomonal activity. Variable gram- positive activity. Primarily hepatically eliminated in bile.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Disulfiram-like reaction with alcohol.
| |
| | |
| |- | | |- |
| | | '''Chloramphenicol''' |
| | | | | |
| '''Cefotaxime sodium'''
| | * Gram-positive pathogens |
| | | * Salmonella |
| Claforan. Injection.
| | * Enterococcus faecium |
| | | * Bacteroides |
| | * Mycoplasma |
| | * Chlamydia |
| | * Rickettsia |
| | | | | |
| '''3rd generation cephalosporin active against gram-positive and gram-negative pathogens. No antipseudomonal activity.'''
| | * Neonates: loading dose of 20 mg/kg followed by |
| | | * Neonates (postnatal age ≤ 7 days): 25 mg/kg/24 hr q 24 hr IV |
| Neonates: ≤7 days: 100 mg/kg/24 hr divided q 12 hr IV or IM; 7 days: 1,200 g 100 mg/kg/24 hr divided q 12 hr IV or IM; | | * Neonates (postnatal age > 7 days): 25 mg/kg/24 hr q 24 hr IV (< 2,000 g); 50 mg/kg/24 hr divided q 12 hr IV (> 2,000 g) |
| | | * Children: 50-75 mg/kg/24 hr divided q 6-8 hr IV or PO |
| 12,000 g: 150 mg/kg/24 hr divided q 8 hr IV or IM.
| | * Adults: 50 mg/kg/24 hr divided q 6 hr IV or PO (max dose: 4 g/24 hr) |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Each gram of drug contains 2.2 mEq sodium. Active metabolite.
| | * Gray-baby syndrome |
| | | * Bone marrow suppression |
| ''Drug interaction: ''Probenecid.
| | * Aplastic anemia |
| | |
| |- | | |- |
| | | '''Ciprofloxacin''' |
| | | | | |
| | | * P. aeruginosa |
| | | * Serratia |
| | * Enterobacter |
| | * Shigella |
| | * Salmonella |
| | * Campylobacter |
| | * N. gonorrhoeae |
| | * H. influenzae |
| | * M. catarrhalis |
| | | | | |
| Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM (meningitis: 200 mg/kg/24 hr divided q 6-8 hr IV).
| | * Neonates: 10 mg/kg q 12 hr PO or IV |
| | | * Children: 15-30 mg/kg/24 hr divided q 12 hr PO or IV |
| | * Adults: 250-750 mg q 12 hr; 200-400 mg IV q 12 hr PO (max dose: 1.5 g/24 hr) |
| | | | | |
| | | * Tendonitis |
| | | * Dizziness |
| | * Confusion |
| | * Crystalluria |
| | * Photosensitivity |
| |- | | |- |
| | | '''Clarithromycin''' |
| | | | | |
| | | * S. aureus |
| | | * Streptococcus |
| | * H. influenzae |
| | * Legionella |
| | * Mycoplasma |
| | * C. trachomatis |
| | | | | |
| Adults: 1-2 g q 8-12 hr IV or IM (max dose: 12 g/24 hr). | | * Children: 15 mg/kg/24 hr divided q 12 hr PO |
| | | * Adults: 250-500 mg q 12 hr PO (max dose: 1 g/24 hr) |
| | | | | |
| | | * Gastrointestinal distress |
| | | * Dyspepsia |
| | * Nausea |
| | * Cramping |
| |- | | |- |
| | | '''Clindamycin''' |
| | | | | |
| '''Cefotetan disodium'''
| | * Gram-positive aerobic pathogens |
| | | * Anaerobic cocci except Enterococcus |
| Cefotan. Injection.
| |
| | |
| | | | | |
| '''2nd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, E. coli, Klebsiella, Proteus, ''and ''Bacteroides. ''Inactive against ''Enterobacter.'''''
| | * Neonates (postnatal age ≤ 7 days): 10 mg/kg/24 hr divided q 12 hr IV or IM (≤ 2,000 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 10 mg/kg/24 hr IV or IM divided q 12 hr (≤ 1,200 g); 15 mg/kg/24 hr divided q 8 hr IV or IM (1,200–2,000 g); 20 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) |
| Children: 40-80 mg/kg/24 hr divided IV or IM q 12 hr. | | * Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO |
| | | * Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO) |
| | | | | |
| ''Cautions: ''Highly protein-bound cephalosporin, poor CNS penetration; -Lactam safety profile (rash, eosinophilia), disulfiram-like reaction with alcohol. Renally eliminated (∼20% in bile).
| | * Diarrhea |
| | | * Nausea |
| | * Pseudomembranous colitis |
| | * Rash |
| |- | | |- |
| | | '''Cloxacillin''' |
| | | | | |
| | | * S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci |
| | |
| | | | | |
| Adults: 2-4 g/24 hr divided q 12 hr IV or IM (max dose: 6 g/24 hr).
| | * Children: 50-100 mg/kg/24 hr divided q 6 hr PO |
| | | * Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr) |
| | | | | |
| | | * Rash |
| | * Eosinophilia |
| |- | | |- |
| | | '''Trimethoprim-Sulfamethoxazole''' |
| | | | | |
| '''Cefoxitin sodium '''Mefoxin. Injection.
| | * Shigella |
| | | * Legionella |
| | * Nocardia |
| | * Chlamydia |
| | * Pneumocystis jirovecii |
| | | | | |
| '''2nd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, E. coli, Klebsiella, Proteus, ''and ''Bacteroides. ''Inactive against ''Enterobacter.'''''
| | * Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO |
| | | * Adults: 160 mg TMP q 12 hr PO |
| | | | | |
| ''Cautions: ''Poor CNS penetration; -Lactam safety profile (rash, eosinophilia). Renally eliminated. Painful given intramuscularly.
| | * Rash |
| | | * Erythema multiforme |
| | * Stevens-Johnson syndrome |
| | * Nausea |
| | * Leukopenia |
| |- | | |- |
| | | '''Demeclocycline''' |
| | | | | |
| | | * Gram-positive cocci except Enterococcus |
| | | * Gram-negative bacilli |
| | * Anaerobes |
| | * Borrelia burgdorferi |
| | * Mycoplasma |
| | * Chlamydia |
| | | | | |
| Neonates: 70-100 mg/kg/24 hr divided q 8-12 hr IV or IM.
| | * Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO |
| | | * Adults: 150 mg PO q 6-8 hr |
| | | | | |
| ''Drug interaction: ''Probenecid.
| | * Teeth staining |
| | | * Photosensitivity |
| | * Diabetes insipidus |
| | * Nausea |
| | * Vomiting |
| | * Diarrhea |
| |- | | |- |
| | | '''Dicloxacillin''' |
| | | | | |
| | | * S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci |
| | |
| | | | | |
| Children: 80-160 mg/kg/24 hr divided q 6-8 hr IV or IM. | | * Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO |
| | | * Adults: 125-500 mg q 6 hr PO |
| | | | | |
| | | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Doripenem''' |
| | | | | |
| | | * Gram-positive cocci |
| | | * Gram-negative bacilli including P. aeruginosa |
| | * Anaerobes |
| | | | | |
| Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr). | | * Adults: 500 mg q 8 hr IV |
| | |
| | | | | |
| | | * Rash |
| | | * Eosinophilia |
| |- | | |- |
| | | '''Doxycycline''' |
| | | | | |
| '''Cefpodoxime proxetil'''
| | * Gram-positive cocci except Enterococcus |
| | | * Gram-negative bacilli |
| Vantin.
| | * Anaerobes |
| | | * B. burgdorferi |
| Tablet: 100 mg, 200 mg.
| | * Mycoplasma |
| | | * Chlamydia |
| Suspension: 50 mg/5 mL, 100 mg/5 mL.
| |
| | |
| | | | | |
| '''3rd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, M. catarrhalis, N. gonorrhoeae,'''''
| | * Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200 mg/24 hr) |
| | | * Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV |
| '''''E. coli, Klebsiella, ''and ''Proteus. ''No antipseudomonal activity.'''
| |
| | |
| Children: 10 mg/kg/24 hr divided q 12 hr PO. | |
| | |
| Adults: 200-800 mg/24 hr divided q 12 hr PO (max dose: 800 mg/24 hr).
| |
| | |
| Uncomplicated gonorrhea: 200 mg PO as single-dose therapy.
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Does not adequately penetrate CNS. Increased bioavailability when taken with food.
| | * Teeth staining |
| | | * Photosensitivity |
| ''Drug interaction: ''Probenecid; antacids and H-2 receptor antagonists may decrease absorption.
| | * Nausea |
| | | * Vomiting |
| | * Diarrhea |
| |- | | |- |
| | | '''Erythromycin''' |
| | | | | |
| '''Cefprozil'''
| | * Gram-positive organisms |
| | | * Corynebacterium diphtheriae |
| Cefzil.
| | * Mycoplasma pneumoniae |
| | |
| Tablet: 250, 500 mg.
| |
| | |
| Suspension: 125 mg/5 mL, 250 mg/5 mL.
| |
| | |
| | | | | |
| '''2nd generation cephalosporin active against ''S. aureus, Streptococcus, H. influenzae, E. coli, M. catarrhalis, Klebsiella, ''and ''Proteus.'''''
| | * Neonates (postnatal age ≤ 7 days): 20 mg/kg/24 hr divided q 12 hr PO |
| | | * Neonates (postnatal age > 7 days): 20 mg/kg/24 hr divided q 12 hr PO (< 1,200 g); 30 mg/kg/24 hr divided q 8 hr PO (> 1,200 g) |
| Children: 30 mg/kg/24 hr divided q 8-12 hr PO.
| | * Children: Usual max dose 2 g/24 hr. Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV. Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV |
| | | * Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO |
| Adults: 500-1,000 mg/24 hr divided q 12 hr PO (max dose: 1.5 g/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Good bioavailability; food does not affect bioavailability.
| | * Cramping |
| | | * Nausea |
| ''Drug interaction: ''Probenecid.
| | * Vomiting |
| | | * Diarrhea |
| | * Hypertrophic pyloric stenosis |
| |- | | |- |
| | | '''Gentamicin''' |
| | | | | |
| '''Ceftazidime'''
| | * E. coli |
| | | * Klebsiella |
| Fortaz, Ceptaz, Tazicer, Tazidime. Injection.
| | * Proteus |
| | | * Enterobacter |
| | * Serratia |
| | * Pseudomonas |
| | | | | |
| '''3rd generation cephalosporin active against gram-positive and gram-negative pathogens, including ''Pseudomonas aeruginosa.'''''
| | * Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q 12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 32.5 mg/kg q 8 hr IV or IM (> 2,000 g) |
| Neonates: Postnatal age ≤7 days: 100 mg/kg/24 hr divided q 12 hr IV or IM; 7 days ≤1,200 g: 100 mg/kg/24 hr divided q 12 hr IV or IM; 1,200 g: 150 mg/kg/24 hr divided q 8 hr IV or IM. | | * Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV once daily |
| | | * Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM |
| Children: 150 mg/kg/24 hr divided q 8 hr IV or IM (meningitis: 150 mg/kg/24 hr IV divided q 8 hr). | |
| | |
| Adults: 1-2 g q 8-12 hr IV or IM (max dose: 8-12 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Increasing pathogen resistance developing with
| | * Ototoxicity |
| | | * Nephrotoxicity |
| long-term, widespread use.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |- | | |- |
| | | '''Imipenem-Cilastatin''' |
| | | | | |
| '''Ceftiaoxime '''Cefizox. Injection.
| | * Gram-positive cocci |
| | | * Gram-negative bacilli including P. aeruginosa |
| | * Anaerobes |
| | | | | |
| '''3rd generation cephalosporin active against gram-positive and gram-negative pathogens. No antipseudomonal activity.'''
| | * Neonates (postnatal age ≤ 7 days): 20 mg/kg q 18-24 hr IV or IM (< 1,200 g); 40 mg/kg divided q 12 hr IV or IM (> 1,200 g) |
| | | * Neonates (postnatal age > 7 days): 40 mg/kg q 12 hr IV or IM (< 2,000 g); 60 mg/kg q 8 hr IV or IM (> 2,000 g) |
| Children: 150 mg/kg/24 hr divided q 6-8 hr IV or IM. Adults: 1-2 g q 6-8 hr IV or IM (max dose: 12 g/24 hr). | | * Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM |
| | | * Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr) |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Probenecid.
| | * Nausea |
| | | * Seizures |
| |- | | |- |
| | | '''Linezolid''' |
| | | | | |
| '''Ceftriaxone sodium'''
| | * Staphylococcus |
| | | * Streptococcus |
| Rocephin. Injection.
| | * E. faecium |
| | | * Enterococcus faecalis |
| | | | | |
| '''3rd generation cephalosporin active against gram-positive and gram-negative pathogens. No antipseudomonal activity.'''
| | * Children: 10 mg/kg q 12 hr IV or PO |
| | | * Adults: Pneumonia: 600 mg q 12 hr IV or PO |
| Neonates: 50-75 mg/kg q 24 hr IV or IM.
| |
| | |
| Children: 50-75 mg/kg q 24 hr IV or IM (meningitis: 75 mg/kg dose 1 then 80-100 mg/kg/24 hr divided q 12-24 hr IV or IM).
| |
| | |
| Adults: 1-2 g q 24 hr IV or IM (max dose: 4 g/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Eliminated via kidney (33-65%) and bile; can cause sludging. Long half-life and dose-dependent protein binding favors q 24 hr rather than q 12 hr dosing. Can add 1% lidocaine for IM injection.
| | * Bone marrow suppression |
| | | * Pseudomembranous colitis |
| | * Nausea |
| | * Diarrhea |
| | * Headache |
| |- | | |- |
| | | '''Loracarbef''' |
| | | | | |
| '''Cefuroxime (cefuroxime axetil for oral administration)'''
| | * S. aureus |
| | | * Streptococcus |
| Ceftin, Kefurox, Zinacef. Injection.
| | * H. influenzae |
| | | * M. catarrhalis |
| Suspension: 125 mg/5 mL. Tablet: 125, 250, 500 mg.
| | * E. coli |
| | | * Klebsiella |
| | * Proteus |
| | | | | |
| '''2nd generation cephalosporin active against S. aureus, ''Streptococcus, H. influenzae, E. coli, M. catarrhalis, Klebsiella, ''and ''Proteus.'''''
| | * Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g) |
| | | * Adults: 200-400 mg q 12 hr PO (max dose: 800 mg/24 hr) |
| Neonates: 40-100 mg/kg/24 hr divided q 12 hr IV or IM. Children: 200-240 mg/kg/24 hr divided q 8 hr IV or IM; PO
| |
| | |
| administration: 20-30 mg/kg/24 hr divided q 8 hr PO. Adults: 750-1,500 mg q 8 hr IV or IM (max dose: 6 g/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated. Food increases PO bioavailability.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |- | | |- |
| | | '''Meropenem''' |
| | | | | |
| '''Cephalexin'''
| | * Gram-positive cocci |
| | | * Gram-negative bacilli including P. aeruginosa |
| Keflex, Keftab. Capsule: 250, 500 mg
| | * Anaerobes |
| | |
| Tablet: 500 mg, 1 g.
| |
| | |
| Suspension: 125 mg/5 mL, 250 mg/5 mL, 100 mg/mL drops.
| |
| | |
| | | | | |
| '''1st generation cephalosporin active against ''S. aureus, Streptococcus, E. coli, Klebsiella, ''and ''Proteus.'''''
| | * Children: 60 mg/kg/24 hr divided q 8 hr IV |
| | | * Adults: 1.5-3 g q 8 hr IV |
| Children: 25-100 mg/kg/24 hr divided q 6-8 hr PO. Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |- | | |- |
| | | '''Metronidazole''' |
| | | | | |
| '''Cephradine'''
| | * Anaerobes |
| | |
| Velosef
| |
| | |
| Capsule: 250, 500 mg.
| |
| | |
| Suspension: 125 mg/5 mL, 250 mg/5 mL.
| |
| | |
| | | | | |
| '''1st generation cephalosporin active against ''S. aureus, Streptococcus, E. coli, Klebsiella, ''and ''Proteus.'''''
| | * Neonates (postnatal age ≤ 7 days): 7.5 mg/kg 48 hr PO or IV (< 1,200 g); 7.5 mg/kg/24 hr q 24 hr PO or IV (1,200–2,000 g); 15 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 5 mg/kg/24 hr divided q 12 hr PO or IV (< 2,000 g); 30 mg/kg/24 hr divided q 12 hr PO or IV (> 2,000 g) |
| Children: 50-100 mg/kg/24 hr divided q 6-12 hr PO. Adults: 250-500 mg q 6-12 hr PO (max dose: 4 g/24 hr). | | * Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV |
| | | * Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr) |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated.
| | * Dizziness |
| | | * Seizures |
| ''Drug interaction: ''Probenecid.
| | * Metallic taste |
| | | * Nausea |
| | * Hypoprothrombinemia |
| | * Disulfiram-like reaction |
| |- | | |- |
| | | '''Mezlocillin''' |
| | | | | |
| '''Chloramphenicol '''Chloromycetin. Injection. Capsule: 250 mg.
| | * E. coli |
| | | * Enterobacter |
| Ophthalmic, otic solutions. Ointment.
| | * Serratia |
| | | * Bacteroides |
| | | | | |
| '''Broad-spectrum protein synthesis inhibitor active against many gram-positive and gram-negative bacteria, ''Salmonella, ''vancomycin-resistant ''Enterococcus faecium, Bacteroides, ''other anaerobes, ''Mycoplasma, Chlamydia, ''and ''Rickettsia''; usually inactive against ''Pseudomonas''.'''
| | * Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 12 hr IV |
| | | * Neonates (postnatal age > 7 days): 225 mg/kg divided q 8 hr IV |
| Neonates: Initial loading dose 20 mg/kg followed 12 hr later by: postnatal age ≤7 days: 25 mg/kg/24 hr q 24 hr IV; 7 days: | | * Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV |
| | | * Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr) |
| ≤2,000 g: 25 mg/kg/24 hr q 24 hr IV; 2,000 g: 50 mg/kg/24 hr divided q 12 hr IV.
| |
| | |
| Children: 50-75 mg/kg/24 hr divided q 6-8 hr IV or PO (meningitis: 75-100 mg/kg/24 hr IV divided q 6 hr). | |
| | |
| Adults: 50 mg/kg/24 hr divided q 6 hr IV or PO (max dose: 4 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''Gray-baby syndrome (from too-high dose in neonate), bone marrow suppression aplastic anemia (monitor hematocrit, free serum iron).
| | * Rash |
| | | * Eosinophilia |
| ''Drug interactions: ''Phenytoin, phenobarbital, rifampin may decrease levels.
| | * Liver transaminases elevation |
| | |
| ''Target serum concentrations: ''Peak 20-30 mg/L; trough 5-10 mg/L.
| |
| | |
| | |
| |- | | |- |
| | | '''Mupirocin''' |
| | | | | |
| '''Ciprofloxacin'''
| | * Staphylococcus |
| | | * Streptococcus |
| Cipro.
| |
| | |
| Tablet: 100, 250, 500, 750 mg.
| |
| | |
| Injection.
| |
| | |
| Ophthalmic solution and ointment. Otic suspension.
| |
| | |
| Oral suspension: 250 and 500 mg/5 mL.
| |
| | |
| | | | | |
| '''Quinolone antibiotic active against ''P. aeruginosa, Serratia, Enterobacter, Shigella, Salmonella, Campylobacter, N. gonorrhoeae, H. influenzae, M. catarrhalis, ''some ''S. aureus, ''and some ''Streptococcus.'''''
| | * Topical application to the skin 2-4 times per day |
| | |
| Neonates: 10 mg/kg q 12 hr PO or IV.
| |
| | |
| Children: 15-30 mg/kg/24 hr divided q 12 hr PO or IV; cystic fibrosis: 20-40 mg/kg/24 hr divided q 8-12 hr PO or IV.
| |
| | |
| Adults: 250-750 mg q 12 hr; 200-400 mg IV q 12 hr PO (max dose: 1.5 g/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''Concerns of joint destruction in juvenile animals not seen in humans; tendonitis, superinfection, dizziness, confusion, crystalluria, some photosensitivity.
| | * Itching |
| | |
| ''Drug interactions: ''Theophylline; magnesium-, aluminum-, or calcium-containing antacids; sucralfate; probenecid; warfarin; cyclosporine.
| |
| | |
| |- | | |- |
| | | '''Nafcillin''' |
| | | | | |
| '''Clarithromycin'''
| | * S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci |
| | |
| Biaxin.
| |
| | |
| Tablet: 250, 500 mg.
| |
| | |
| Suspension: 125 mg/5 mL, 250 mg/5 mL.
| |
| | |
| | | | | |
| '''Macrolide antibiotic with activity against ''S. aureus, Streptococcus, H. influenzae, Legionella, Mycoplasma, ''and'''
| | * Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75 mg/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 75 mg/kg/q 8 hr IV (< 2,000 g); 100 mg/kg divided q 6-8 hr IV (> 2,000 g) |
| '''''C. trachomatis.'''''
| | * Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV |
| | | * Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr) |
| Children: 15 mg/kg/24 hr divided q 12 hr PO. | |
| | |
| Adults: 250-500 mg q 12 hr PO (max dose: 1 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''Adverse events less than erythromycin; gastrointestinal upset, dyspepsia, nausea, cramping.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interactions: ''Same as erythromycin: astemizole carbamazepine, terfenadine cyclosporine, theophylline, digoxin, tacrolimus.
| | * Phlebitis |
| | | * Neutropenia |
| |- | | |- |
| | | '''Nalidixic acid''' |
| | | | | |
| '''Clindamycin'''
| | * E. coli |
| | | * Enterobacter |
| Cleocin.
| | * Klebsiella |
| | | * Proteus |
| Capsule: 75, 150, 300 mg. Suspension: 75 mg/5 mL. Injection.
| |
| | |
| Topical solution, lotion, and gel. Vaginal cream.
| |
| | |
| | | | | |
| '''Protein synthesis inhibitor active against most gram-positive aerobic and anaerobic cocci except ''Enterococcus.'''''
| | * Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO |
| | | * Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO |
| Neonates: Postnatal age ≤7 days 200 g; 10 mg/kg/24 hr divided q 12 hr IV or IM; 2,000 g: 15 mg/kg/24 hr divided q 8 hr IV or IM;
| |
| | |
| 7 days 1,200 g: 10 mg/kg/24 hr IV or IM divided q 12 hr; 1,200-2,000 g: 15 mg/kg/24 hr divided q 8 hr IV or IM; 2,000 g: 20 mg/kg/24 hr divided q 8 hr IV or IM.
| |
| | |
| Children: 10-40 mg/kg/24 hr divided q 6-8 hr IV, IM, or PO.
| |
| | |
| Adults: 150-600 mg q 6-8 hr IV, IM, or PO (max dose: 5 g/24 hr IV or IM or 2 g/24 hr PO). | |
| | |
| | | | | |
| ''Cautions: ''Diarrhea, nausea, ''Clostridium difficile''–associated colitis, rash. Administer slow IV over 30-60 min. Topically active as an acne treatment.
| | * Vertigo |
| | | * Dizziness |
| | * Rash |
| |- | | |- |
| | | '''Neomycin''' |
| | | | | |
| '''Cloxacillin sodium'''
| | * Gastrointestinal flora |
| | |
| Tegopen.
| |
| | |
| Capsule: 250, 500 mg. Suspension: 125 mg/5 mL.
| |
| | |
| | | | | |
| '''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci except ''Enterococcus ''and coagulase- negative staphylococci.'''
| | * Infants: 50 mg/kg/24 hr divided q 6 hr PO |
| | | * Children: 50-100 mg/kg/24 hr divided q 6-8 hr PO |
| Children: 50-100 mg/kg/24 hr divided q 6 hr PO. Adults: 250-500 mg q 6 hr PO (max dose: 4 g/24 hr). | | * Adults: 500-2,000 mg/dose q 6-8 hr PO |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Primarily hepatically eliminated; requires dose reduction in renal disease. Food decreases bioavailability.
| | * Cramping |
| | | * Diarrhea |
| ''Drug interaction: ''Probenecid.
| | * Rash |
| | | * Ototoxicity |
| | * Nephrotoxicity |
| |- | | |- |
| | | '''Nitrofurantoin''' |
| | | | | |
| '''Co-trimoxazole (trimethoprim- sulfamethoxazole; TMP-SMZ)'''
| | * Gram-positive pathogens |
| | | * Gram-negative pathogens |
| Bactrim, Cotrim, Septra, Sulfatrim. Tablet: SMZ 400 mg and TMP 80 mg.
| |
| | |
| Tablet DS: SMZ 800 mg and TMP 160 mg. Suspension: SMZ 200 mg and TMP
| |
| | |
| 40 mg/5 mL. Injection.
| |
| | |
| | | | | |
| '''Antibiotic combination with sequential antagonism of bacterial folate synthesis with broad antibacterial activity: ''Shigella, Legionella, Nocardia, Chlamydia, Pneumocystis jiroveci. ''Dosage based on TMP component.'''
| | * Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose: 400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr) |
| | | * Adults: 50-100 mg/24 hr divided q 6 hr PO |
| Children: 6-20 mg TMP/kg/24 hr or IV divided q 12 hr PO. | |
| | |
| ''Pneumocystis carinii ''pneumonia: 15-20 mg TMP/kg/24 hr divided q 12 hr PO or IV.
| |
| | |
| ''P. carinii ''prophylaxis: 5 mg TMP/kg/24 hr or 3 times/wk PO. Adults: 160 mg TMP q 12 hr PO.
| |
| | |
| | | | | |
| ''Cautions: ''Drug dosed on TMP (trimethoprim) component. Sulfonamide skin reactions: rash, erythema multiforme,
| | * Vertigo |
| | | * Dizziness |
| Stevens-Johnson syndrome, nausea, leukopenia. Renal and hepatic elimination; reduce dose in renal failure.
| | * Rash |
| | | * Jaundice |
| ''Drug interactions: ''Protein displacement with warfarin, possibly phenytoin, cyclosporine.
| | * Interstitial pneumonitis |
| | |
| |- | | |- |
| | | '''Ofloxacin''' |
| | | | | |
| '''Demeclocycline'''
| | * Gram-positive pathogens |
| | | * Gram-negative pathogens |
| Declomycin.
| | * Anaerobes |
| | | * Chlamydia trachomatis |
| Tablet: 150, 300 mg.
| |
| | |
| Capsule: 150 mg.
| |
| | |
| | | | | |
| '''Tetracycline active against most gram-positive cocci except ''Enterococcus'', many gram-negative bacilli, anaerobes, ''Borrelia burgdorferi ''(Lyme disease), ''Mycoplasma, ''and ''Chlamydia.'''''
| | * Child (< 12 yr): Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then 1-2 drops qid for 5 days. Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days. Otitis externa: 5 drops into affected ear bid for 10 days |
| | | * Child (> 12 yr) and adults: Ophthalmic solution doses same as for younger children. Otitis externa: 10 drops bid for 10–14 days as for younger children |
| Children: 8-12 mg/kg/24 hr divided q 6-12 hr PO. Adults: 150 mg PO q 6-8 hr.
| |
| | |
| Syndrome of inappropriate antidiuretic hormone secretion: 900- 1,200 mg/24 hr or 13-15 mg/kg/24 hr divided q 6-8 hr PO with dose reduction based on response to 600-900 mg/24 hr.
| |
| | |
| | | | | |
| ''Cautions: ''Teeth staining, possibly permanent (if administered 8 yr of age) with prolonged use; photosensitivity, diabetes insipidus, nausea, vomiting, diarrhea, superinfections.
| | * Burning |
| | | * Stinging |
| ''Drug interactions: ''Aluminum-, calcium-, magnesium-, zinc- and iron-containing food, milk, dairy products may decrease absorption.
| | * Eye redness |
| | | * Dizziness |
| |- | | |- |
| | | '''Oxacillin''' |
| | | | | |
| '''Dicloxacillin'''
| | * S. aureus and other gram-positive cocci except Enterococcus and coagulase-negative staphylococci |
| | |
| Dynapen, Pathocil.
| |
| | |
| Capsule: 125, 250, 500 mg. Suspension: 62.5 mg/5 mL.
| |
| | |
| | | | | |
| '''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci except ''Enterococcus ''and coagulase- negative staphylococci.'''
| | * Neonates (postnatal age ≤ 7 days): 50 mg/kg/24 hr divided q 12 hr IV (< 2,000 g); 75 mg/kg/24 hr IV divided q 8 hr IV (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 50 mg/kg/24 hr IV divided q 12 hr IV (< 1,200 g); 75 mg/kg/24 hr divided q 8 hr IV (1,200–2,000 g); 100 mg/kg/24 hr IV divided q 6 hr IV (> 2,000 g) |
| Children: 12.5-100 mg/kg/24 hr divided q 6 hr PO. Adults: 125-500 mg q 6 hr PO. | | * Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV |
| | | * Children: PO 50-100 mg/kg/24 hr divided q 4-6 hr IV |
| | * Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr) |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Primarily renally (65%) and bile (30%) elimination. Food may decrease bioavailability.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Probenecid.
| | * Neutropenia |
| | |
| |- | | |- |
| | | '''Penicillin G''' |
| | | | | |
| '''Doripenem '''Doribax. Injection.
| | * S. pneumoniae |
| | | * Group A Streptococcus |
| | * N. gonorrhoeae |
| | * N. meningitidis |
| | | | | |
| '''Carbapenem antibiotic with broad-spectrum activity against gram-positive cocci and gram-negative bacilli, including'''
| | * Neonates (postnatal age ≤ 7 days): 50,000 units/kg/24 hr divided q 12 hr IV or IM (< 2,000 g); 75,000 units/kg/24 hr divided q 8 hr IV or IM (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 50,000 units/kg/24 hr divided q 12 hr IV (< 1,200 g); 75,000 units/kg/24 hr q 8 hr IV (1,200–2,000 g); 100,000 units/kg/24 hr divided q 6 hr IV (> 2,000 g) |
| '''''P. aeruginosa ''and anaerobes.'''
| | * Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr) |
| | | * Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM |
| Children: dose unknown. Adults: 500 mg q 8 hr IV. | |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile; does not undergo hepatic metabolism. Renal elimination (70-75%); dose adjustment for renal failure.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interactions: ''Valproic acid, probenecid.
| | * Allergy |
| | | * Seizures |
| |- | | |- |
| | | '''Penicillin G, benzathine''' |
| | | | | |
| '''Doxycycline '''Vibramycin, Doxy. Injection.
| | * Group A Streptococcus |
| | |
| Capsule: 50, 100 mg.
| |
| | |
| Tablet: 50, 100 mg. Suspension: 25 mg/5 mL. Syrup: 50 mg/5 mL.
| |
| | |
| | | | | |
| '''Tetracycline antibiotic active against most gram-positive cocci except ''Enterococcus, ''many gram-negative bacilli, anaerobes,'''
| | * Neonates: 50,000 units/kg IM once |
| | | * Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose: 1.2-2.4 million units/dose) |
| '''''B. burgdorferi ''(Lyme disease), ''Mycoplasma, ''and ''Chlamydia.'''''
| | * Adults: 1.2 million units IM q 3-4 wk |
| | |
| Children: 2-5 mg/kg/24 hr divided q 12-24 hr PO or IV (max dose: 200 mg/24 hr).
| |
| | |
| Adults: 100-200 mg/24 hr divided q 12-24 hr PO or IV. | |
| | |
| | | | | |
| ''Cautions: ''Teeth staining, possibly permanent (8 yr of age) with prolonged use; photosensitivity, nausea, vomiting, diarrhea, superinfections.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interactions: ''Aluminum-, calcium-, magnesium-, zinc-, iron-, kaolin-, and pectin-containing products, food, milk, dairy products may decrease absorption. Carbamazepine, rifampin, barbiturates may decrease half-life.
| | * Allergy |
| | |
| |- | | |- |
| | | '''Penicillin G, procaine''' |
| | | | | |
| '''Erythromycin'''
| | * Gram-positive pathogens |
| | |
| E-Mycin, Ery-Tab, Ery-C, Ilosone. Estolate 125, 500 mg.
| |
| | |
| Tablet EES: 200 mg.
| |
| | |
| Tablet base: 250, 333, 500 mg. Suspension: estolate 125 mg/5 mL,
| |
| | |
| 250 mg/5 mL, EES 200 mg/5 mL, 400 mg/5 mL.
| |
| | |
| Estolate drops: 100 mg/mL. EES drops:
| |
| | |
| 100 mg/2.5 mL. Available in combination with sulfisoxazole (Pediazole), dosed on erythromycin content.
| |
| | |
| | | | | |
| '''Bacteriostatic macrolide antibiotic most active against gram- positive organisms, ''Corynebacterium diphtheriae, ''and ''Mycoplasma pneumoniae.'''''
| | * Neonates: 50,000 units/kg/24 hr IM |
| | | * Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose: 4.8 million units/dose) |
| Neonates: Postnatal age ≤7 days: 20 mg/kg/24 hr divided q 12 hr PO; | | * Adults: 0.6-4.8 million units q 12-24 hr IM |
| | |
| 7 days 1,200 g: 20 mg/kg/24 hr divided q 12 hr PO; 1,200 g:
| |
| | |
| 30 mg/kg/24 hr divided q 8 hr PO (give as 5 mg/kg/dose q 6 hr to
| |
| | |
| improve feeding intolerance). Children: Usual max dose 2 g/24 hr.
| |
| | |
| Base: 30-50 mg/kg/24 hr divided q 6-8 hr PO. Estolate: 30-50 mg/kg/24 hr divided q 8-12 hr PO. Stearate: 20-40 mg/kg/24 hr divided q 6 hr PO. Lactobionate: 20-40 mg/kg/24 hr divided q 6-8 hr IV.
| |
| | |
| Gluceptate: 20-50 mg/kg/24 hr divided q 6 hr IV; usual max dose 4 g/24 hr IV.
| |
| | |
| Adults: Base: 333 mg PO q 8 hr; estolate/stearate/base: 250-500 mg q 6 hr PO.
| |
| | |
| | | | | |
| ''Cautions: ''Motilin agonist leading to marked abdominal cramping, nausea, vomiting, diarrhea. Associated with hypertrophic pyloric stenosis in young infants. Many different salts with questionable tempering of gastrointestinal adverse events. Rare cardiac toxicity with IV use. Dose of salts differ. Topical formulation for treatment of acne.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interactions: ''Antagonizes hepatic CYP 3A4 activity: astemizole, carbamazepine, terfenadine, cyclosporine, theophylline, digoxin, tacrolimus, carbamazepine.
| | * Allergy |
| | |
| |- | | |- |
| | | '''Penicillin V''' |
| | | | | |
| '''Gentamicin '''Garamycin. Injection.
| | * S. pneumoniae |
| | | * N. gonorrhoeae |
| Ophthalmic solution, ointment, topical cream.
| | * N. meningitidis |
| | |
| | | | | |
| '''Aminoglycoside antibiotic active against gram-negative bacilli, especially ''E. coli, Klebsiella, Proteus, Enterobacter, Serratia, ''and ''Pseudomonas.'''''
| | * Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO |
| | | * Adults: 125-500 mg q 6-8 hr PO (max dose: 3 g/24 hr) |
| Neonates: Postnatal age ≤7 days 1,200-2,000 g: 2.5 mg/kg q
| |
| | |
| 12-18 hr IV or IM; 2,000 g: 2.5 mg/kg q 12 hr IV or IM; postnatal
| |
| | |
| age 7 days 1,200-2,000 g: 2.5 mg/kg q 8-12 hr IV or IM;
| |
| | |
| 2,000 g: 2.5 mg/kg q 8 hr IV or IM.
| |
| | |
| Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM. Alternatively
| |
| | |
| may administer 5-7.5 mg/kg/24 hr IV once daily. Intrathecal: Preservative-free preparation for intraventricular or
| |
| | |
| intrathecal use: neonate: 1 mg/24 hr; children: 1-2 mg/24 hr IT; adults: 4-8 mg/24 hr.
| |
| | |
| Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM.
| |
| | |
| | | | | |
| ''Cautions: ''Anaerobes, ''S. pneumoniae, ''and other ''Streptococcus ''are resistant. May cause ototoxicity and nephrotoxicity. Monitor renal function. Drug eliminated renally. Administered IV over 30-60 min.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interactions: ''May potentiate other ototoxic and nephrotoxic drugs.
| | * Allergy |
| | |
| ''Target serum concentrations: ''Peak 6-12 mg/L; trough 2 mg/L with intermittent daily dose regimens only.
| |
| | |
| |- | | |- |
| | | '''Piperacillin''' |
| | | | | |
| '''Imipenem-cilastatin'''
| | * E. coli |
| | | * Enterobacter |
| Primaxin. Injection.
| | * Serratia |
| | | * P. aeruginosa |
| | * Bacteroides |
| | | | | |
| '''Carbapenem antibiotic with broad-spectrum activity against gram-positive cocci and gram-negative bacilli, including'''
| | * Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV |
| | | * Neonates (postnatal age > 7 days): 200 mg/kg divided q 6-8 hr IV |
| '''''P. aeruginosa ''and anaerobes. No activity against'''
| | * Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV |
| | | * Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV |
| '''''Stenotrophomonas maltophilia.'''''
| |
| | |
| Neonates: Postnatal age ≤7 days 1,200 g: 20 mg/kg q 18-24 hr IV or IM; 1,200 g: 40 mg/kg divided q 12 hr IV or IM; postnatal age | |
| | |
| 7 days 1,200-2,000 g: 40 mg/kg q 12 hr IV or IM; 2,000 g: 60 mg/kg q 8 hr IV or IM.
| |
| | |
| Children: 60-100 mg/kg/24 hr divided q 6-8 hr IV or IM. | |
| | |
| Adults: 2-4 g/24 hr divided q 6-8 hr IV or IM (max dose: 4 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia), nausea, seizures. Cilastatin possesses no antibacterial activity; reduces renal imipenem metabolism. Primarily renally eliminated.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Possibly ganciclovir.
| | * Serum sickness-like reaction |
| | |
| |- | | |- |
| | | '''Piperacillin-Tazobactam''' |
| | | | | |
| '''Linezolid'''
| | * S. aureus |
| | | * H. influenzae |
| Zyvox.
| | * E. coli |
| | | * Enterobacter |
| Tablet: 400, 600 mg.
| | * Serratia |
| | | * Acinetobacter |
| Oral suspension: 100 mg/5 mL. Injection: 100 mg/5 mL.
| | * P. aeruginosa |
| | | * Bacteroides |
| | | | | |
| '''Oxazolidinone antibiotic active against gram-positive cocci (especially drug-resistant organisms), including ''Staphylococcus, Streptococcus, E. faecium, ''and ''Enterococcus faecalis. ''Interferes with protein synthesis by binding to 50S ribosome subunit.'''
| | * Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM |
| | | * Adults: 3.375 g q 6-8 hr IV or IM |
| Children: 10 mg/kg q 12 hr IV or PO. | |
| | |
| Adults: Pneumonia: 600 mg q 12 hr IV or PO; skin infections: 400 mg q 12 hr IV or PO. | |
| | |
| | | | | |
| ''Adverse events: ''Myelosuppression, pseudomembranous colitis, nausea, diarrhea, headache.
| | * Rash |
| | | * Eosinophilia |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |- | | |- |
| | | '''Quinupristin-Dalfopristin''' |
| | | | | |
| '''Loracarbef'''
| | * E. faecium, vancomycin-resistant |
| | | * S. aureus, methicillin-resistant |
| Lorabid.
| |
| | |
| Capsule: 200 mg.
| |
| | |
| Suspension: 100 mg/5 mL, 200 mg/5 mL.
| |
| | |
| | | | | |
| '''Carbacephem very closely related to cefaclor (2nd generation cephalosporin) active against ''S. aureus, Streptococcus, H. influenzae, M. catarrhalis, E. coli, Klebsiella, ''and ''Proteus.'''''
| | * Children and adults: 7.5 mg/kg q 8 hr IV |
| | |
| Children: 30 mg/kg/24 hr divided q 12 hr PO (max dose: 2 g). Adults: 200-400 mg q 12 hr PO (max dose: 800 mg/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia). Renally eliminated.
| | * Pain |
| | | * Edema |
| ''Drug interaction: ''Probenecid.
| | * Phlebitis |
| | | * Nausea |
| | * Diarrhea |
| |- | | |- |
| | | '''Sulfadiazine''' |
| | | | | |
| '''Meropenem '''Merrem. Injection.
| | * E. coli |
| | | * P. mirabilis |
| | * Klebsiella |
| | | | | |
| '''Carbapenem antibiotic with broad-spectrum activity against gram-positive cocci and gram-negative bacilli, including ''P. aeruginosa ''and anaerobes. No activity against ''Stenotrophomonas maltophilia.'''''
| | * Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO with folinic acid |
| | | * Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid |
| Children: 60 mg/kg/24 hr divided q 8 hr IV meningitis: 120 mg/ kg/24 hr (max dose: 6 g/24 hr) q 8 hr IV. | |
| | |
| Adults: 1.5-3 g q 8 hr IV.
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile; appears to possess less CNS excitation than imipenem. 80% renal elimination.
| | * Rash |
| | | * Stevens-Johnson syndrome |
| ''Drug interaction: ''Probenecid.
| | * Nausea |
| | | * Leukopenia |
| | * Crystalluria |
| |- | | |- |
| | | '''Sulfamethoxazole''' |
| | | | | |
| '''Metronidazole'''
| | * Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections |
| | |
| Flagyl, Metro-IV, generic. Topical gel, vaginal gel. Injection.
| |
| | |
| Tablet: 250, 500 mg.
| |
| | |
| | | | | |
| '''Highly effective in the treatment of infections due to anaerobes.'''
| | * Children: 50-60 mg/kg/24 hr divided q 12 hr PO |
| | | * Adults: 1 g/dose q 12 hr PO (max dose: 3 g/24 hr) |
| Neonates: 1,200 g: 7.5 mg/kg 48 hr PO or IV; postnatal age ≤7 days 1,200-2,000 g: 7.5 mg/kg/24 hr q 24 hr PO or IV; 2,000 g: 15 mg/ kg/24 hr divided q 12 hr PO or IV; postnatal age 7 days
| |
| | |
| 1,200-2,000 g: 15 mg/kg/24 hr divided q 12 hr PO or IV; 2,000 g: 30 mg/kg/24 hr divided q 12 hr PO or IV. | |
| | |
| Children: 30 mg/kg/24 hr divided q 6-8 hr PO or IV.
| |
| | |
| Adults: 30 mg/kg/24 hr divided q 6 hr PO or IV (max dose: 4 g/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''Dizziness, seizures, metallic taste, nausea, disulfiram-like reaction with alcohol. Administer IV slow over 30-60 min. Adjust dose with hepatic impairment.
| | * Rash |
| | | * Stevens-Johnson syndrome |
| ''Drug interactions: ''Carbamazepine, rifampin, phenobarbital may enhance metabolism; may increase levels of warfarin, phenytoin, lithium.
| | * Nausea |
| | | * Leukopenia |
| | * Crystalluria |
| |- | | |- |
| | | '''Sulfisoxazole''' |
| | | | | |
| '''Mezlocillin sodium'''
| | * Bacteria associated with otitis media, chronic bronchitis, and lower urinary tract infections |
| | |
| Mezlin. Infection.
| |
| | |
| | | | | |
| <center>'''Extended-spectrum penicillin active against ''E. coli, Enterobacter, Serratia, ''and ''Bacteroides; ''limited antipseudomonal activity. '''Neonates: Postnatal age ≤7 days: 150 mg/kg/24 hr divided q 12 hr IV;</center>
| | * Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr) |
| | | * Adults: 4-8 g/24 hr divided q 4-6 hr PO |
| 7 days: 225 mg/kg divided q 8 hr IV.
| |
| | |
| Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV; cystic fibrosis | |
| | |
| 300-450 mg/kg/24 hr IV.
| |
| | |
| Adults: 2-4 g/dose q 4-6 hr IV (max dose: 12 g/24 hr). | |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 1.8 mEq sodium. Interferes with platelet aggregation with high doses; increases noted in liver function test results. Renally eliminated. Inactivated by
| | * Rash |
| | | * Stevens-Johnson syndrome |
| <center>-lactamase enzyme.</center>
| | * Nausea |
| | | * Leukopenia |
| ''Drug interaction: ''Probenecid.
| | * Crystalluria |
| | |
| |- | | |- |
| | | '''Ticarcillin''' |
| | | | | |
| '''Mupirocin '''Bactroban. Ointment.
| | * E. coli |
| | | * Enterobacter |
| | * Serratia |
| | * P. aeruginosa |
| | * Bacteroides |
| | | | | |
| '''Topical antibiotic active against ''Staphylococcus ''and'''
| | * Neonates (postnatal age ≤ 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV |
| | | * Neonates (postnatal age > 7 days): 150 mg/kg/24 hr divided q 8-12 hr IV (< 1,200 g); 150 mg/kg/24 hr divided q 12 hr IV (1,200–2,000 g); 300 mg/kg/24 hr divided q 6-8 hr IV (> 2,000 g) |
| '''''Streptococcus.'''''
| | * Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV |
| | | * Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr) |
| Topical application: Nasal (eliminate nasal carriage) and to the skin 2-4 times per day.
| |
| | |
| | | | | |
| ''Caution: ''Minimal systemic absorption as drug metabolized within the skin.
| | * Rash |
| | | * Eosinophilia |
| | * Liver transaminases elevation |
| |- | | |- |
| | | '''Ticarcillin-Clavulanate''' |
| | | | | |
| '''Nafcillin sodium '''Nafcil, Unipen. Injection. Capsule: 250 mg.
| | * S. aureus |
| | | * H. influenzae |
| Tablet: 500 mg.
| | * Enterobacter |
| | | * E. coli |
| | * Serratia |
| | * P. aeruginosa |
| | * Acinetobacter |
| | * Bacteroides |
| | | | | |
| '''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci, except ''Enterococcus ''and coagulase-negative staphylococci.'''
| | * Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM |
| | | * Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr) |
| Neonates: Postnatal age ≤7 days 1,200-2,000 g: 50 mg/kg/24 hr divided q 12 hr IV or IM; 2,000 g: 75 mg/kg/24 hr divided q 8 hr IV or IM; postnatal age 7 days 1,200-2,000 g: 75 mg/kg/q 8 hr;
| |
| | |
| 2,000 g: 100 mg/kg divided q 6-8 hr IV (meningitis: 200 mg/ kg/24 hr divided q 6 hr IV).
| |
| | |
| Children: 100-200 mg/kg/24 hr divided q 4-6 hr IV.
| |
| | |
| Adults: 4-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr).
| |
| | |
| | | | | |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia), phlebitis; painful given intramuscularly; oral absorption highly variable and erratic (not recommended).
| | * Rash |
| | | * Eosinophilia |
| ''Adverse effect: ''Neutropenia.
| | * Liver transaminases elevation |
| | |
| |- | | |- |
| | | '''Tigecycline''' |
| | | | | |
| '''Nalidixic acid'''
| | * Enterobacteriaceae including ESBL producers |
| | | * Streptococcus |
| NegGram.
| | * Staphylococcus |
| | | * Anaerobes |
| Tablet: 250, 500, 1,000 mg. Suspension: 250 mg/5 mL.
| |
| | |
| | | | | |
| '''1st generation quinolone effective for short-term treatment of lower urinary tract infections caused by ''E. coli, Enterobacter, Klebsiella, ''and ''Proteus.'''''
| | * Adults: 100 mg loading dose followed by 50 mg q 12 hr IV |
| | |
| Children: 50-55 mg/kg/24 hr divided q 6 hr PO; suppressive therapy 25-33 mg/kg/24 hr divided q 6-8 hr PO.
| |
| | |
| Adults: 1 g q 6 hr PO; suppressive therapy: 500 mg q 6 hr PO.
| |
| | |
| | | | | |
| ''Cautions: ''Vertigo, dizziness, rash. Not for use in systemic infections.
| | * Photosensitivity |
| | | * Hypersensitivity |
| ''Drug interactions: ''Liquid antacids.
| | * Hepatic impairment |
| | |
| |- | | |- |
| | | '''Tobramycin''' |
| | | | | |
| '''Neomycin sulfate '''Mycifradin, generic. Tablet: 500 mg.
| | * E. coli |
| | | * Klebsiella |
| Topical cream, ointment. Solution: 125 mg/5 mL.
| | * Enterobacter |
| | | * Serratia |
| | * Proteus |
| | * Pseudomonas |
| | | | | |
| '''Aminoglycoside antibiotic used for topical application or orally before surgery to decrease gastrointestinal flora (nonabsorbable) and hyperammonemia.'''
| | * Neonates (postnatal age ≤ 7 days): 2.5 mg/kg q12-18 hr IV or IM (< 2,000 g); 2.5 mg/kg q 12 hr IV or IM (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 2.5 mg/kg q 8-12 hr IV or IM (< 2,000 g); 2.5 mg/kg q 8 hr IV or IM (> 2,000 g) |
| Infants: 50 mg/kg/24 hr divided q 6 hr PO. Children: 50-100 mg/kg/24 hr divided q 6-8 hr PO. Adults: 500-2,000 mg/dose q 6-8 hr PO.
| | * Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM; 5-7.5 mg/kg/24 hr IV |
| | | * Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM |
| | | | | |
| ''Cautions: ''In patients with renal dysfunction because small amount absorbed may accumulate.
| | * Ototoxicity |
| | | * Nephrotoxicity |
| ''Adverse events: ''Primarily related to topical application, abdominal cramps, diarrhea, rash. Aminoglycoside ototoxicity and nephrotoxicity if absorbed.
| |
| | |
| |- | | |- |
| | | '''Trimethoprim''' |
| | | | | |
| '''Nitrofurantoin'''
| | * E. coli |
| | | * Klebsiella |
| Furadantin, Furan, Macrodantin. Capsule: 50, 100 mg.
| | * P. mirabilis |
| | | * Enterobacter |
| Extended-release capsule: 100 mg. Macrocrystal: 50, 100 mg. Suspension: 25 mg/5 mL.
| | * P. jirovecii |
| | |
| | | | | |
| '''Effective in the treatment of lower urinary tract infections caused by gram-positive and gram-negative pathogens.'''
| | * Children (< 12 yr): 4-6 mg/kg/24 hr divided q 12 hr PO |
| | | * Children (> 12 yr) and adults: 100-200 mg q 12 hr PO |
| Children: 5-7 mg/kg/24 hr divided q 6 hr PO (max dose: | |
| | |
| 400 mg/24 hr); suppressive therapy 1-2.5 mg/kg/24 hr divided q 12-24 hr PO (max dose: 100 mg/24 hr).
| |
| | |
| Adults: 50-100 mg/24 hr divided q 6 hr PO.
| |
| | |
| | | | | |
| ''Cautions: ''Vertigo, dizziness, rash, jaundice, interstitial pneumonitis. Do not use with moderate to severe renal dysfunction.
| | * Megaloblastic anemia |
| | | * Bone marrow suppression |
| ''Drug interactions: ''Liquid antacids.
| | * Nausea |
| | | * Epigastric distress |
| | * Rash |
| |- | | |- |
| | | '''Vancomycin''' |
| | | | | |
| '''Ofloxacin'''
| | * Gram-positive pathogens including Staphylococcus, S. pneumoniae, and Enterococcus |
| | | * C. difficile |
| Ocuflox 0.3% ophthalmic solution: 1, 5,
| |
| | |
| <center>10 mL.</center>
| |
| | |
| Floxin 0.3% otic solution: 5, 10 mL.
| |
| | |
| | | | | |
| '''Quinolone antibiotic for treatment of conjunctivitis or corneal ulcers (ophthalmic solution) and otitis externa or chronic suppurative otitis media (otic solution) caused by susceptible gram-positive, gram-negative, anaerobic bacteria, or ''Chlamydia trachomatis.'''''
| | * Neonates (postnatal age > 7 days): 15 mg/kg/24 hr divided q 24 hr IV (< 1,200 g); 15 mg/kg/24 hr divided q 12-18 hr IV (1,200–2,000 g); 30 mg/kg/24 hr divided q 12 hr IV (> 2,000 g) |
| | | * Neonates (postnatal age > 7 days): 15 mg/kg/24 hr divided q 24 hr IV (< 1,200 g); 15 mg/kg/24 hr divided q 8-12 hr IV (1,200–2,000 g); 45 mg/kg/24 hr divided q 8 hr IV (> 2,000 g) |
| ''Child ''''1-12 yr:''
| | * Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV |
| | | * C. difficile–associated colitis: 40-50 mg/kg/24 hr divided q 6-8 hr PO; 40-50 mg/kg/24 hr divided q 6-8 hr PO |
| Conjunctivitis: 1-2 drops in affected eye(s) q 2-4 hr for 2 days, then
| |
| | |
| 1-2 drops qid for 5 days.
| |
| | |
| Corneal ulcers: 1-2 drops q 30 min while awake and at 4 hours at night for 2 days, then 1-2 drops hourly for 5 days while awake, then 1-2 drops q 6 hr for 2 days.
| |
| | |
| Otitis externa (otic solution): 5 drops into affected ear bid for 10 days.
| |
| | |
| Chronic suppurative otitis media: treat for 14 days.
| |
| | |
| ''Child ''''12 yr and adults: ''Ophthalmic solution doses same as for younger children. Otitis externa (otic solution): Use 10 drops bid for 10 or 14 days as for younger children.
| |
| | |
| | | | | |
| ''Adverse events: ''Burning, stinging, eye redness (ophthalmic solution), dizziness with otic solution if not warmed.
| | * Ototoxicity |
| | | * Nephrotoxicity |
| |-
| |
| |
| |
| '''Oxacillin sodium '''Prostaphlin. Injection.
| |
| | |
| Capsule: 250, 500 mg. Suspension: 250 mg/5 mL.
| |
| | |
| |
| |
| '''Penicillinase-resistant penicillin active against ''S. aureus ''and other gram-positive cocci, except ''Enterococcus ''and coagulase-negative staphylococci.'''
| |
| | |
| Neonates: Postnatal age ≤7 days 1,200-2,000 g: 50 mg/kg/24 hr divided q 12 hr IV; 2,000 g: 75 mg/kg/24 hr IV divided q 8 hr IV; postnatal age 7 days 1,200 g: 50 mg/kg/24 hr IV divided q 12 hr IV; 1,200-2,000 g: 75 mg/kg/24 hr divided q 8 hr IV; 2,000 g:
| |
| | |
| 100 mg/kg/24 hr IV divided q 6 hr IV.
| |
| | |
| Infants: 100-200 mg/kg/24 hr divided q 4-6 hr IV. Children: PO 50-100 mg/kg/24 hr divided q 4-6 hr IV.
| |
| | |
| Adults: 2-12 g/24 hr divided q 4-6 hr IV (max dose: 12 g/24 hr).
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia).
| |
| | |
| Moderate oral bioavailability (35-65%). Primarily renally eliminated.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| ''Adverse effect: ''Neutropenia.
| |
| | |
| |-
| |
| |
| |
| '''Penicillin G '''Injection. Tablets.
| |
| | |
| |
| |
| '''Penicillin active against most gram-positive cocci; ''S. pneumoniae ''(resistance is increasing), group A streptococcus, and some gram-negative bacteria (e.g., ''N. gonorrhoeae, N. meningitidis'').'''
| |
| | |
| Neonates: Postnatal age ≤7 days 1,200-2,000 g: 50,000 units/ kg/24 hr divided q 12 hr IV or IM (meningitis: 100,000 units/
| |
| | |
| kg/24 hr divided q 12 hr IV or IM); 2,000 g: 75,000 units/kg/24 hr divided q 8 hr IV or IM (meningitis: 150,000 units/kg/24 hr divided q 8 hr IV or IM); postnatal age 7 days ≤1,200 g: 50,000 units/ kg/24 hr divided q 12 hr IV (meningitis: 100,000 units/kg/24 hr divided q 12 hr IV); 1,200-2,000 g: 75,000 units/kg/24 hr q 8 hr IV (meningitis: 225,000 units/kg/24 hr divided q 8 hr IV); 2,000 g: 100,000 units/kg/24 hr divided q 6 hr IV (meningitis: 200,000 units/ kg/24 hr divided q 6 hr IV).
| |
| | |
| Children: 100,000-250,000 units/kg/24 hr divided q 4-6 hr IV or IM (max dose: 400,000 units/kg/24 hr).
| |
| | |
| Adults: 2-24 million units/24 hr divided q 4-6 hr IV or IM.
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia), allergy, seizures with excessive doses particularly in patients with marked renal disease. Substantial pathogen resistance. Primarily renally eliminated.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Penicillin G, benzathine'''
| |
| | |
| Bicillin. Injection.
| |
| | |
| |
| |
| '''Long-acting repository form of penicillin effective in the treatment of infections responsive to persistent, low penicillin concentrations (1-4 wk), e.g., group A streptococcus pharyngitis, rheumatic fever prophylaxis.'''
| |
| | |
| Neonates 1,200 g: 50,000 units/kg IM once.
| |
| | |
| Children: 300,000-1.2 million units/kg q 3-4 wk IM (max dose:
| |
| | |
| 1.2-2.4 million units/dose).
| |
| | |
| Adults: 1.2 million units IM q 3-4 wk.
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia), allergy. Administer by IM injection only. Substantial pathogen resistance. Primarily renally eliminated.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Penicillin G, procaine'''
| |
| | |
| Crysticillin. Injection.
| |
| | |
| |
| |
| '''Repository form of penicillin providing low penicillin concentrations for 12 hr.'''
| |
| | |
| Neonates 1,200 g: 50,000 units/kg/24 hr IM.
| |
| | |
| Children: 25,000-50,000 units/kg/24 hr IM for 10 days (max dose:
| |
| | |
| 4.8 million units/dose).
| |
| | |
| Gonorrhea: 100,000 units/kg (max dose: 4.8 million units/24 hr) IM once with probenecid 25 mg/kg (max dose: 1 g)
| |
| | |
| Adults: 0.6-4.8 million units q 12-24 hr IM.
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia) allergy. Administer by IM injection only. Substantial pathogen resistance. Primarily renally eliminated.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Penicillin V'''
| |
| | |
| Pen VK, V-Cillin K.
| |
| | |
| Tablet: 125, 250, 500 mg.
| |
| | |
| Suspension: 125 mg/5 mL, 250 mg/5 mL.
| |
| | |
| |
| |
| '''Preferred oral dosing form of penicillin, active against most gram-positive cocci; ''S. pneumoniae ''(resistance is increasing), other ''Streptococcus, ''and some gram-negative bacteria (e.g.,'''
| |
| | |
| '''''N. gonorrhoeae, N. meningitidis'').'''
| |
| | |
| Children: 25-50 mg/kg/24 hr divided q 4-8 hr PO. Adults: 125-500 mg q 6-8 hr PO (max dose: 3 g/24 hr).
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia), allergy, seizures with excessive doses particularly in patients with renal disease. Substantial pathogen resistance. Primarily renally eliminated. Inactivated by penicillinase.
| |
| | |
| ''Drug interaction'': Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Piperacillin '''Pipracil. Injection.
| |
| | |
| |
| |
| '''Extended-spectrum penicillin active against ''E. coli, Enterobacter, Serratia, P. aeruginosa, ''and ''Bacteroides.'''''
| |
| | |
| Neonates: Postnatal age ≤7 days 150 mg/kg/24 hr divided q 8-12 hr IV; 7 days; 200 mg/kg divided q 6-8 hr IV.
| |
| | |
| Children: 200-300 mg/kg/24 hr divided q 4-6 hr IV; cystic fibrosis: 350-500 mg/kg/24 hr IV.
| |
| | |
| Adults: 2-4 g/dose q 4-6 hr (max dose: 24 g/24 hr) IV.
| |
| | |
| |
| |
| ''Cautions'': -Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 1.9 mEq sodium. Interferes with platelet aggregation/serum sickness-like reaction with high doses; increases in liver function tests. Renally eliminated. Inactivated by penicillinase.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Piperacillin-tazobactam'''
| |
| | |
| Zosyn. Injection.
| |
| | |
| |
| |
| '''Extended-spectrum penicillin (piperacillin) combined with a'''
| |
| | |
| β-lactamase inhibitor (tazobactam) active against ''S. aureus, H. influenzae, E. coli, Enterobacter, Serratia, Acinetobacter, P. aeruginosa, ''and ''Bacteroides.'''''
| |
| | |
| Children: 300-400 mg/kg/24 hr divided q 6-8 hr IV or IM. Adults: 3.375 g q 6-8 hr IV or IM.
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 1.9 mEq sodium.
| |
| | |
| Interferes with platelet aggregation, serum sickness–like reaction with high doses, increases in liver function test results. Renally eliminated.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Quinupristin/dalfopristin'''
| |
| | |
| Synercid.
| |
| | |
| IV injection: powder for reconstitution, 10 mL contains 150 mg quinupristin,
| |
| | |
| <center>350 mg dalfopristin.</center>
| |
| | |
| |
| |
| '''Streptogramin antibiotic (quinupristin) active against vancomycin-resistant ''E. faecium ''(VRE) and methicillin- resistant ''S. aureus ''(MRSA)''. ''Not active against ''E. faecalis.'''''
| |
| | |
| Children and adults: VRE: 7.5 mg/kg q 8 hr IV for VRE; skin infections:
| |
| | |
| 7.5 mg/kg q 12 hr IV.
| |
| | |
| |
| |
| ''Adverse events: ''Pain, edema, or phlebitis at injection site, nausea, diarrhea.
| |
| | |
| ''Drug interactions: ''Synercid is a potent inhibitor of CYP 3A4.
| |
| | |
| |-
| |
| |
| |
| '''Sulfadiazine'''
| |
| | |
| Tablet: 500 mg.
| |
| | |
| |
| |
| '''Sulfonamide antibiotic primarily indicated for the treatment of lower urinary tract infections due to ''E. coli, P. mirabilis, ''and ''Klebsiella.'''''
| |
| | |
| Toxoplasmosis:
| |
| | |
| Neonates: 100 mg/kg/24 hr divided q 12 hr PO with pyrimethamine 1 mg/kg/24 hr PO (with folinic acid).
| |
| | |
| Children: 120-200 mg/kg/24 hr divided q 6 hr PO with pyrimethamine 2 mg/kg/24 hr divided q 12 hr PO ≥3 days then 1 mg/kg/24 hr (max dose: 25 mg/24 hr) with folinic acid.
| |
| | |
| Rheumatic fever prophylaxis: ≤30 kg: 500 mg/24 hr q 24 hr PO;
| |
| | |
| 30 kg: 1 g/24 hr q 24 hr PO.
| |
| | |
| |
| |
| ''Cautions: ''Rash, Stevens-Johnson syndrome, nausea, leukopenia, crystalluria. Renal and hepatic elimination; avoid use with renal disease. Half-life ∼10 hr.
| |
| | |
| ''Drug interactions: ''Protein displacement with warfarin, phenytoin, methotrexate.
| |
| | |
| |-
| |
| |
| |
| '''Sulfamethoxazole'''
| |
| | |
| Gantanol. Tablet: 500 mg.
| |
| | |
| Suspension: 500 mg/5 mL.
| |
| | |
| |
| |
| '''Sulfonamide antibiotic used for the treatment of otitis media, chronic bronchitis, and lower urinary tract infections due to susceptible bacteria.'''
| |
| | |
| Children: 50-60 mg/kg/24 hr divided q 12 hr PO. Adults: 1 g/dose q 12 hr PO (max dose: 3 g/24 hr).
| |
| | |
| |
| |
| ''Cautions: ''Rash, Stevens-Johnson syndrome, nausea, leukopenia, crystalluria. Renal and hepatic elimination; avoid use with renal disease. Half-life 12 hr. Initial dose often a loading dose (doubled).
| |
| | |
| ''Drug interactions: ''Protein displacement with warfarin, phenytoin, methotrexate.
| |
| | |
| |-
| |
| |
| |
| '''Sulfisoxazole '''Gantrisin. Tablet: 500 mg.
| |
| | |
| Suspension: 500 mg/5 mL. Ophthalmic solution, ointment.
| |
| | |
| |
| |
| '''Sulfonamide antibiotic used for the treatment of otitis media, chronic bronchitis, and lower urinary tract infections due to susceptible bacteria.'''
| |
| | |
| Children: 120-150 mg/kg/24 hr divided q 4-6 hr PO (max dose: 6 g/24 hr).
| |
| | |
| Adults: 4-8 g/24 hr divided q 4-6 hr PO.
| |
| | |
| |
| |
| ''Cautions: ''Rash, Stevens-Johnson syndrome, nausea, leukopenia, crystalluria. Renal and hepatic elimination; avoid use with renal disease. Half-life ∼7-12 hr. Initial dose often a loading dose (doubled).
| |
| | |
| ''Drug interactions: ''Protein displacement with warfarin, phenytoin, methotrexate.
| |
| | |
| |-
| |
| |
| |
| '''Ticarcillin '''Ticar. Injection.
| |
| | |
| |
| |
| '''Extended-spectrum penicillin active against ''E. coli, Enterobacter, Serratia, P. aeruginosa, ''and ''Bacteroides.'''''
| |
| | |
| Neonates: Postnatal age ≤7 days 2,000 g: 150 mg/kg/24 hr divided q 8-12 hr IV; 7 days 2,000 g: 225 mg/kg/24 hr divided q 8 hr IV;
| |
| | |
| 7 days 1,200 g: 150 mg/kg/24 hr divided q 12 hr IV; 1,200-
| |
| | |
| 2,000 g: 225 mg/kg/24 hr divided q 8 hr IV; 2,000 g: 300 mg/
| |
| | |
| kg/24 hr divided q 6-8 hr IV.
| |
| | |
| Children: 200-400 mg/kg/24 hr divided q 4-6 hr IV; cystic fibrosis: 400-600 mg/kg/24 hr IV.
| |
| | |
| Adults: 2-4 g/dose q 4-6 hr IV (max dose: 24 g/24 hr).
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 5-6 mEq sodium. Interferes with platelet aggregation; increases in liver function tests. Renally eliminated. Inactivated by penicillinase.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Ticarcillin-clavulanate'''
| |
| | |
| Timentin. Injection.
| |
| | |
| |
| |
| '''Extended-spectrum penicillin (ticarcillin) combined with a'''
| |
| | |
| β-lactamase inhibitor (clavulanate) active against ''S. aureus, H. influenzae, Enterobacter, E. coli, Serratia, P. aeruginosa, Acinetobacter, ''and ''Bacteroides.'''''
| |
| | |
| Children: 280-400 mg/kg/24 hr q 4-8 hr IV or IM.
| |
| | |
| Adults: 3.1 g q 4-8 hr IV or IM (max dose: 18-24 g/24 hr).
| |
| | |
| |
| |
| ''Cautions: ''-Lactam safety profile (rash, eosinophilia); painful given intramuscularly; each gram contains 5-6 mEq sodium. Interferes with platelet aggregation; increases in liver function tests. Renally eliminated.
| |
| | |
| ''Drug interaction: ''Probenecid.
| |
| | |
| |-
| |
| |
| |
| '''Tigecycline '''Tygacil. Injection.
| |
| | |
| |
| |
| '''Tetracycline-class antibiotic (glycylcycline) active against Enterobacteriaceae, including ESBL producers; streptococci (including VRE); staphylococci (including MRSA); and anaerobes.'''
| |
| | |
| Children: unknown.
| |
| | |
| Adults: 100 mg loading dose followed by 50 mg q 12 hr IV.
| |
| | |
| |
| |
| ''Cautions: ''Pregnancy; children under 8 yr of age; photosensitivity; hypersensitivity to tetracyclines; hepatic impairment (~60% hepatic clearance).
| |
| | |
| ''Drug interaction: ''Warfarin; mycophenolate mofetil.
| |
| | |
| |-
| |
| |
| |
| '''Tobramycin '''Nebcin, Tobrex. Injection.
| |
| | |
| Ophthalmic solution, ointment.
| |
| | |
| |
| |
| '''Aminoglycoside antibiotic active against gram-negative bacilli, especially ''E. coli, Klebsiella, Enterobacter, Serratia, Proteus, ''and ''Pseudomonas.'''''
| |
| | |
| Neonates: Postnatal age ≤7 days, 1,200-2,000 g: 2.5 mg/kg q
| |
| | |
| 12-18 hr IV or IM; 2,000 g: 2.5 mg/kg q 12 hr IV or IM; postnatal
| |
| | |
| age 7 days, 1,200-2,000 g: 2.5 mg/kg q 8-12 hr IV or IM;
| |
| | |
| 2,000 g: 2.5 mg/kg q 8 hr IV or IM.
| |
| | |
| Children: 2.5 mg/kg/24 hr divided q 8-12 hr IV or IM. Alternatively
| |
| | |
| may administer 5-7.5 mg/kg/24 hr IV. Preservative-free preparation for intraventricular or intrathecal use: neonate: 1 mg/24 hr; children: 1-2 mg/24 hr; adults: 4-8 mg/24 hr.
| |
| | |
| Adults: 3-6 mg/kg/24 hr divided q 8 hr IV or IM.
| |
| | |
| |
| |
| ''Cautions: S. pneumoniae, ''other ''Streptococcus, ''and anaerobes are resistant. May cause ototoxicity and nephrotoxicity. Monitor renal function. Drug eliminated renally. Administered IV over 30-60 min.
| |
| | |
| ''Drug interactions: ''May potentiate other ototoxic and nephrotoxic drugs.
| |
| | |
| ''Target serum concentrations: ''Peak 6-12 mg/L; trough 2 mg/L.
| |
| | |
| |-
| |
| |
| |
| '''Trimethoprim '''Proloprim, Trimpex. Tablet: 100, 200 mg
| |
| | |
| |
| |
| '''Folic acid antagonist effective in the prophylaxis and treatment of ''E. coli, Klebsiella, P. mirabilis, ''and ''Enterobacter ''urinary tract infections; ''P. carinii ''pneumonia.'''
| |
| | |
| Children: For urinary tract infection: 4-6 mg/kg/24 hr divided q 12 hr PO.
| |
| | |
| Children ''12 yr and adults: ''100-200 mg q 12 hr PO. ''P. carinii ''pneumonia (with dapsone): 15-20 mg/kg/24 hr divided q 6 hr for 21 days PO.
| |
| | |
| |
| |
| ''Cautions: ''Megaloblastic anemia, bone marrow suppression, nausea, epigastric distress, rash.
| |
| | |
| ''Drug interactions: ''Possible interactions with phenytoin, cyclosporine, rifampin, warfarin.
| |
| | |
| |-
| |
| |
| |
| '''Vancomycin '''Vancocin, Luphocin. Injection.
| |
| | |
| Capsule: 125 mg, 250 mg. Suspension.
| |
| | |
| |
| |
| '''Glycopeptide antibiotic active against most gram-positive pathogens including ''Staphylococcus ''(including ''MRSA ''and coagulase-negative staphylococci), ''S. pneumoniae ''including penicillin-resistant strains, ''Enterococcus ''(resistance is increasing), and ''C. difficile–as''sociated colitis.'''
| |
| | |
| Neonates: Postnatal age ≤7 days, 1,200 g: 15 mg/kg/24 hr divided q 24 hr IV; 1,200-2,000 g: 15 mg/kg/24 hr divided q 12-18 hr IV;
| |
| | |
| 2,000 g: 30 mg/kg/24 hr divided q 12 hr IV; postnatal age 7
| |
| | |
| days, 1,200 g: 15 mg/kg/24 hr divided q 24 hr IV; 1,200-2,000 g:
| |
| | |
| 15 mg/kg/24 hr divided q 8-12 hr IV; 2,000 g: 45 mg/kg/24 hr
| |
| | |
| divided q 8 hr IV.
| |
| | |
| Children: 45-60 mg/kg/24 hr divided q 8-12 hr IV; ''C. difficile''– associated colitis; 40-50 mg/kg/24 hr divided q 6-8 hr PO.
| |
| | |
| 40-50 mg/kg/24 hr divided q 6-8 hr PO.
| |
| | |
| |
| |
| ''Cautions: ''Ototoxicity and nephrotoxicity particularly when co-administered with other ototoxic and nephrotoxic drugs.
| |
| | |
| Infuse IV over 45-60 min. Flushing (red man syndrome) associated with rapid IV infusions, fever, chills, phlebitis (central line is preferred). Renally eliminated.
| |
| | |
| ''Target serum concentrations: ''Peak (1 hr after
| |
| | |
| 1 hr infusion) 30-40 mg/L; trough 5-10 mg/L.
| |
| | |
| |} | | |} |